<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01987011</url>
  </required_header>
  <id_info>
    <org_study_id>MG1109_P3</org_study_id>
    <nct_id>NCT01987011</nct_id>
  </id_info>
  <brief_title>Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers</brief_title>
  <official_title>Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety of the investigational
      vaccine in the subjects during their participation in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MG1109 is purified, inactivated influenza viral antigen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving post-vaccination Hemagglutination Inhibition(HI) antibody titer â‰¥ 1:40</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects achieving post-vaccination seroconversion for Hemagglutination Inhibition(HI) antibody</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GMR(Geometric Mean Ratio) of Hemagglutination Inhibition(HI) antibody titer at post-vaccination compared to pre-vaccination</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects reporting solicited adverse events from the date of vaccination until 7 days after each vaccination</measure>
    <time_frame>Each vaccination ~ 7 days after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects reporting unsolicited adverse events from the date of 1st vaccination until 24weeks after 2nd vaccination</measure>
    <time_frame>1st vaccination ~ 24 weeks after 2nd vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT(Geometric Mean Titer) of Hemagglutination Inhibition(HI) antibody titer pre-vaccination and post-vaccination</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT(Geometric Mean Titer) and GMR(Geometric Mean Ratio) of neutralizing antibody titer pre-vaccination and post-vaccination</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs(body temperature, pulse)</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The results of physical examinations</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab results(Hematology, Blood chemistry, Urinalysis)</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>MG1109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MG1109 0.5 mL Intramuscularly injection, twice at an interval of 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo(for MG1109) 0.5 mL Intramuscularly injection, twice at an interval of 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG1109</intervention_name>
    <arm_group_label>MG1109</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults who are available for follow-up during the study

        Exclusion Criteria:

          -  Subjects with history of exposure to the H5N1 subtype or H5N1 subtype vaccine

          -  Subjects with immune system disorder including immune deficiency disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo Joo Kim, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Inchon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University Of Korea ST. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <last_update_submitted>July 1, 2015</last_update_submitted>
  <last_update_submitted_qc>July 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avian influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

